Анализ показывает, что Mainz Biomed превосходит Freedom Acquisition I по пяти из восьми ключевых финансовых показателей

Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and Freedom Acquisition I (NASDAQ:FACT – Get Free Report) are both small-cap industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation. Profitability This table compares Mainz Biomed and Freedom Acquisition I’s net margins, return on equity and return on assets. Earnings and Valuation This table compares Mainz Biomed and Freedom Acquisition I”s revenue, earnings per share and valuation. Freedom Acquisition I has lower revenue, but higher earnings than Mainz Biomed. Institutional & Insider Ownership 55.8% of Freedom Acquisition I shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 0.2% of Freedom Acquisition I shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Volatility & Risk Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Freedom Acquisition I has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Analyst Ratings This is a breakdown of current recommendations and price targets for Mainz Biomed and Freedom Acquisition I, as reported by MarketBeat. Summary Mainz Biomed beats Freedom Acquisition I on 5 of the 8 factors compared between the two stocks. About Mainz Biomed Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. About Freedom Acquisition I Freedom Acquisition I Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. Freedom Acquisition I Corp. was incorporated in 2020 and is based in New York, New York. Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.